Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Triple Negative Breast Neoplasms 7Breast Neoplasms 5Small Cell Lung Carcinoma 2Ovarian Neoplasms 2Melanoma 2Cervical Cancer Metastatic 2Thyroid Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Neoadjuvant Therapy 1NSCLC 1Esophageal Squamous Cell Carcinoma 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1BRCA-Mutated Breast Carcinoma 1

Interventions

Iodine-131 14trametinib 9dabrafenib 9Thyroidectomy 9Surgical Procedures, Operative 9lenvatinib 8Thyroxine 8Magnetic Resonance Spectroscopy 8pembrolizumab 7Paclitaxel 7anlotinib 6Thyrotropin Alfa 6selpercatinib 5Sorafenib 5Saline Solution 5Radiofrequency Ablation 5Everolimus 5pazopanib 4Vemurafenib 4Sunitinib 4Radiotherapy 4Nivolumab 4Fluorodeoxyglucose F18 4Dexmedetomidine 4Cyclophosphamide 4Biopsy, Fine-Needle 4Biopsy 4Bevacizumab 4apatinib 3Triiodothyronine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thyroid Neoplasms × famitinib × Clear all
NCT06146985 2023-11-28

Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer

Ruijin Hospital

Phase 2 Unknown
67 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡